Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.
Standard
Close association between HER-2 amplification and overexpression in human tumors of non-breast origin. / Tapia, Coya; Glatz, Katharina; Novotny, Hedvika; Lugli, Alessandro; Horcic, Milo; Seemayer, Christian A; Tornillo, Luigi; Terracciano, Luigi; Spichtin, Hanspeter; Mirlacher, Martina; Simon, Ronald; Sauter, Guido.
In: MODERN PATHOL, Vol. 20, No. 2, 2, 2007, p. 192-198.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Close association between HER-2 amplification and overexpression in human tumors of non-breast origin.
AU - Tapia, Coya
AU - Glatz, Katharina
AU - Novotny, Hedvika
AU - Lugli, Alessandro
AU - Horcic, Milo
AU - Seemayer, Christian A
AU - Tornillo, Luigi
AU - Terracciano, Luigi
AU - Spichtin, Hanspeter
AU - Mirlacher, Martina
AU - Simon, Ronald
AU - Sauter, Guido
PY - 2007
Y1 - 2007
N2 - The relationship between HER-2 overexpression and gene amplification is well evaluated in breast cancers but remains unclear or controversial in many other tumor entities. Therefore, we tested the HER-2 status in more than 120 different tumor entities. 5751 tumor samples were analyzed on TMAs by immunohistochemistry (Hercept-Test, DAKO) and fluorescence in situ hybridization (PathVysion, Abbott-Vysis) under highly standardized conditions. HER-2 overexpression (score 2/3+) and amplification occurred most often in breast cancers but was also seen in 18 other tumor entities including cancers of the urinary bladder (amplification in 14.3%, overexpression in 6.7%), stomach (8.3/4.9%), endometrium (6.6/6.8%), lung (2.8/3.1%) and ovary (2.3/1.2%). Remarkably, a strong association between overexpression and amplification was seen in all examined cancer entities. Trastuzumab therapy is highly efficient in HER-2 amplified breast cancer both in metastatic disease and as an adjuvant therapy. A variety of other tumor entities including frequent neoplasms and cancers with often limited therapeutic options have similar patterns of HER-2 alterations as observed in breast cancer (ie high overexpression due to high level gene amplification). Such tumor entities should be carefully evaluated for a possible utility of trastuzumab treatment.
AB - The relationship between HER-2 overexpression and gene amplification is well evaluated in breast cancers but remains unclear or controversial in many other tumor entities. Therefore, we tested the HER-2 status in more than 120 different tumor entities. 5751 tumor samples were analyzed on TMAs by immunohistochemistry (Hercept-Test, DAKO) and fluorescence in situ hybridization (PathVysion, Abbott-Vysis) under highly standardized conditions. HER-2 overexpression (score 2/3+) and amplification occurred most often in breast cancers but was also seen in 18 other tumor entities including cancers of the urinary bladder (amplification in 14.3%, overexpression in 6.7%), stomach (8.3/4.9%), endometrium (6.6/6.8%), lung (2.8/3.1%) and ovary (2.3/1.2%). Remarkably, a strong association between overexpression and amplification was seen in all examined cancer entities. Trastuzumab therapy is highly efficient in HER-2 amplified breast cancer both in metastatic disease and as an adjuvant therapy. A variety of other tumor entities including frequent neoplasms and cancers with often limited therapeutic options have similar patterns of HER-2 alterations as observed in breast cancer (ie high overexpression due to high level gene amplification). Such tumor entities should be carefully evaluated for a possible utility of trastuzumab treatment.
M3 - SCORING: Zeitschriftenaufsatz
VL - 20
SP - 192
EP - 198
JO - MODERN PATHOL
JF - MODERN PATHOL
SN - 0893-3952
IS - 2
M1 - 2
ER -
